As per Intent Market Research, the Pharmacogenomics Market was valued at USD 9.1 Billion in 2024-e and will surpass USD 16.2 Billion by 2030; growing at a CAGR of 10.2% during 2025 - 2030.
The pharmacogenomics market is evolving rapidly as it integrates genomics into drug development and personalized medicine, enabling healthcare providers to tailor treatments based on an individual's genetic profile. This field combines the power of genetic testing and pharmacology, offering the potential to optimize drug efficacy and reduce adverse effects. With increasing healthcare demands for precision medicine, the market for pharmacogenomics is expanding, fueled by advancements in sequencing technologies and growing awareness of genetic testing's role in improving patient outcomes.
Kits and Assays Are Largest Product Type Owing to Widespread Usage
Kits and assays dominate the pharmacogenomics market, driven by their widespread use in clinical settings and research environments. These products enable healthcare professionals to assess genetic variations that influence drug responses, allowing for more personalized treatment strategies. The demand for pharmacogenomics kits and assays is increasing as hospitals, diagnostic laboratories, and research institutes seek to implement genetic testing as part of routine clinical workflows.
With ongoing innovations in assay designs and improvements in turnaround time, kits and assays are becoming more accessible and affordable, leading to their widespread adoption. Their integration into oncology, cardiology, and neurology practices, where personalized treatment regimens are particularly beneficial, is a major factor driving the growth of this product type.
.JPG)
Oncology Application Leads Market Due to Rising Demand for Personalized Cancer Treatments
Oncology is the leading application in the pharmacogenomics market, owing to the increasing need for personalized cancer therapies. Cancer treatment often involves identifying specific genetic mutations and molecular markers that influence tumor behavior and drug response. Pharmacogenomics testing allows clinicians to choose the most effective chemotherapy or targeted therapy based on the patient's unique genetic makeup, improving treatment efficacy and minimizing side effects.
As cancer prevalence continues to rise globally, the demand for pharmacogenomics solutions in oncology is expected to grow. The development of companion diagnostics and targeted therapies further drives this growth, allowing clinicians to select treatments that are tailored to the genetic profile of the patient’s cancer, significantly improving patient outcomes.
Hospitals Are the Largest End-User Due to Increasing Adoption of Precision Medicine
Hospitals represent the largest end-user segment in the pharmacogenomics market, driven by the growing adoption of precision medicine in clinical practice. Healthcare providers are increasingly using pharmacogenomic tests to optimize drug therapies for a variety of conditions, including cancer, cardiovascular diseases, and neurological disorders. The ability to offer personalized treatment plans based on genetic data is making pharmacogenomics an essential tool in modern healthcare.
In particular, hospitals that specialize in cancer care, cardiology, and neurology are integrating pharmacogenomic testing into their standard diagnostic procedures. As healthcare institutions recognize the value of personalized treatments in improving patient outcomes, hospitals are becoming the largest consumers of pharmacogenomics products and services.
North America Dominates the Market Due to Advanced Healthcare Infrastructure and Research Initiatives
North America leads the pharmacogenomics market, owing to its advanced healthcare infrastructure, strong research base, and high adoption of precision medicine. The United States, in particular, is a major player, with numerous leading research institutions, pharmaceutical companies, and healthcare providers at the forefront of pharmacogenomics innovation.
Government initiatives, including funding for pharmacogenomics research and insurance coverage for genetic testing, are driving the adoption of pharmacogenomics in clinical practice. Additionally, North American healthcare providers are increasingly incorporating pharmacogenomic testing into routine clinical care, enhancing patient outcomes and contributing to the region's dominant market position.
.JPG)
Competitive Landscape and Key Players
The pharmacogenomics market is highly competitive, with key players such as Thermo Fisher Scientific, Illumina, Roche, Agilent Technologies, and Qiagen leading the charge. These companies offer a wide range of pharmacogenomic products, including kits, assays, sequencing instruments, and software solutions that enable personalized medicine applications.
With the ongoing advancements in next-generation sequencing (NGS) and the integration of artificial intelligence (AI) in data analysis, the competitive landscape is becoming increasingly dynamic. Companies are focusing on expanding their product portfolios, improving accuracy, and offering comprehensive solutions to address the growing demand for personalized medicine across various therapeutic areas, including oncology, neurology, and cardiology.
Recent Developments:
- Thermo Fisher Scientific, Inc. introduced a new pharmacogenomic testing kit for oncology applications.
- Myriad Genetics, Inc. expanded its psychiatry-focused pharmacogenomic panel with additional biomarkers.
- Illumina, Inc. collaborated with global academic institutions to develop NGS-based pharmacogenomics solutions.
- Quest Diagnostics acquired a regional diagnostic service to enhance its pharmacogenomics capabilities.
- 23andMe, Inc. launched an integrated pharmacogenomics report as part of its consumer health offerings.
List of Leading Companies:
- Illumina, Inc.
- Thermo Fisher Scientific, Inc.
- Myriad Genetics, Inc.
- Quest Diagnostics Incorporated
- Laboratory Corporation of America Holdings (LabCorp)
- 23andMe, Inc.
- Centogene N.V.
- F. Hoffmann-La Roche AG
- Qiagen N.V.
- OneOme LLC
- Admera Health, LLC
- Genetic Technologies Limited
- MDxHealth SA
- Opko Health, Inc.
- PerkinElmer, Inc.
Report Scope:
|
Report Features |
Description |
|
Market Size (2024-e) |
USD 9.1 Billion |
|
Forecasted Value (2030) |
USD 16.2 Billion |
|
CAGR (2025 – 2030) |
10.2% |
|
Base Year for Estimation |
2024-e |
|
Historic Year |
2023 |
|
Forecast Period |
2025 – 2030 |
|
Report Coverage |
Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments |
|
Segments Covered |
Global Pharmacogenomics Market by Product Type (Kits and Assays, Instruments, Software and Services), by Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Microarray, Others), by Application (Oncology, Neurology, Cardiology, Psychiatry, Pain Management, Others), by End-User (Hospitals, Diagnostic Laboratories, Academic and Research Institutes, Others); Insights & Forecast (2024 – 2030) |
|
Regional Analysis |
North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Australia, India, and Rest of Asia-Pacific), Latin America (Brazil, Argentina, and Rest of Latin America), Middle East & Africa (Saudi Arabia, UAE, Rest of Middle East & Africa) |
|
Major Companies |
Illumina, Inc., Thermo Fisher Scientific, Inc., Myriad Genetics, Inc., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings (LabCorp), 23andMe, Inc., F. Hoffmann-La Roche AG, Qiagen N.V., OneOme LLC, Admera Health, LLC, Genetic Technologies Limited, MDxHealth SA, PerkinElmer, Inc. |
|
Customization Scope |
Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements |
|
1. Introduction |
|
1.1. Market Definition |
|
1.2. Scope of the Study |
|
1.3. Research Assumptions |
|
1.4. Study Limitations |
|
2. Research Methodology |
|
2.1. Research Approach |
|
2.1.1. Top-Down Method |
|
2.1.2. Bottom-Up Method |
|
2.1.3. Factor Impact Analysis |
|
2.2. Insights & Data Collection Process |
|
2.2.1. Secondary Research |
|
2.2.2. Primary Research |
|
2.3. Data Mining Process |
|
2.3.1. Data Analysis |
|
2.3.2. Data Validation and Revalidation |
|
2.3.3. Data Triangulation |
|
3. Executive Summary |
|
3.1. Major Markets & Segments |
|
3.2. Highest Growing Regions and Respective Countries |
|
3.3. Impact of Growth Drivers & Inhibitors |
|
3.4. Regulatory Overview by Country |
|
4. Pharmacogenomics Market, by Product Type (Market Size & Forecast: USD Million, 2023 – 2030) |
|
4.1. Kits and Assays |
|
4.2. Instruments |
|
4.3. Software and Services |
|
5. Pharmacogenomics Market, by Technology (Market Size & Forecast: USD Million, 2023 – 2030) |
|
5.1. Polymerase Chain Reaction (PCR) |
|
5.2. Next-Generation Sequencing (NGS) |
|
5.3. Microarray |
|
5.4. Others |
|
6. Pharmacogenomics Market, by Application (Market Size & Forecast: USD Million, 2023 – 2030) |
|
6.1. Oncology |
|
6.2. Neurology |
|
6.3. Cardiology |
|
6.4. Psychiatry |
|
6.5. Pain Management |
|
6.6. Others |
|
7. Pharmacogenomics Market, by End-User (Market Size & Forecast: USD Million, 2023 – 2030) |
|
7.1. Hospitals |
|
7.2. Diagnostic Laboratories |
|
7.3. Academic and Research Institutes |
|
7.4. Others |
|
8. Regional Analysis (Market Size & Forecast: USD Million, 2023 – 2030) |
|
8.1. Regional Overview |
|
8.2. North America |
|
8.2.1. Regional Trends & Growth Drivers |
|
8.2.2. Barriers & Challenges |
|
8.2.3. Opportunities |
|
8.2.4. Factor Impact Analysis |
|
8.2.5. Technology Trends |
|
8.2.6. North America Pharmacogenomics Market, by Product Type |
|
8.2.7. North America Pharmacogenomics Market, by Technology |
|
8.2.8. North America Pharmacogenomics Market, by Application |
|
8.2.9. North America Pharmacogenomics Market, by End-User |
|
8.2.10. By Country |
|
8.2.10.1. US |
|
8.2.10.1.1. US Pharmacogenomics Market, by Product Type |
|
8.2.10.1.2. US Pharmacogenomics Market, by Technology |
|
8.2.10.1.3. US Pharmacogenomics Market, by Application |
|
8.2.10.1.4. US Pharmacogenomics Market, by End-User |
|
8.2.10.2. Canada |
|
8.2.10.3. Mexico |
|
*Similar segmentation will be provided for each region and country |
|
8.3. Europe |
|
8.4. Asia-Pacific |
|
8.5. Latin America |
|
8.6. Middle East & Africa |
|
9. Competitive Landscape |
|
9.1. Overview of the Key Players |
|
9.2. Competitive Ecosystem |
|
9.2.1. Level of Fragmentation |
|
9.2.2. Market Consolidation |
|
9.2.3. Product Innovation |
|
9.3. Company Share Analysis |
|
9.4. Company Benchmarking Matrix |
|
9.4.1. Strategic Overview |
|
9.4.2. Product Innovations |
|
9.5. Start-up Ecosystem |
|
9.6. Strategic Competitive Insights/ Customer Imperatives |
|
9.7. ESG Matrix/ Sustainability Matrix |
|
9.8. Manufacturing Network |
|
9.8.1. Locations |
|
9.8.2. Supply Chain and Logistics |
|
9.8.3. Product Flexibility/Customization |
|
9.8.4. Digital Transformation and Connectivity |
|
9.8.5. Environmental and Regulatory Compliance |
|
9.9. Technology Readiness Level Matrix |
|
9.10. Technology Maturity Curve |
|
9.11. Buying Criteria |
|
10. Company Profiles |
|
10.1. Illumina, Inc. |
|
10.1.1. Company Overview |
|
10.1.2. Company Financials |
|
10.1.3. Product/Service Portfolio |
|
10.1.4. Recent Developments |
|
10.1.5. IMR Analysis |
|
*Similar information will be provided for other companies |
|
10.2. Thermo Fisher Scientific, Inc. |
|
10.3. Myriad Genetics, Inc. |
|
10.4. Quest Diagnostics Incorporated |
|
10.5. Laboratory Corporation of America Holdings (LabCorp) |
|
10.6. 23andMe, Inc. |
|
10.7. Centogene N.V. |
|
10.8. F. Hoffmann-La Roche AG |
|
10.9. Qiagen N.V. |
|
10.10. OneOme LLC |
|
10.11. Admera Health, LLC |
|
10.12. Genetic Technologies Limited |
|
10.13. MDxHealth SA |
|
10.14. Opko Health, Inc. |
|
10.15. PerkinElmer, Inc. |
|
11. Appendix |
A comprehensive market research approach was employed to gather and analyze data on the Pharmacogenomics Market. In the process, the analysis was also done to analyze the parent market and relevant adjacencies to measure the impact of them on the Pharmacogenomics Market. The research methodology encompassed both secondary and primary research techniques, ensuring the accuracy and credibility of the findings.
.jpg)
Secondary Research
Secondary research involved a thorough review of pertinent industry reports, journals, articles, and publications. Additionally, annual reports, press releases, and investor presentations of industry players were scrutinized to gain insights into their market positioning and strategies.
Primary Research
Primary research involved conducting in-depth interviews with industry experts, stakeholders, and market participants across the E-Waste Management ecosystem. The primary research objectives included:
- Validating findings and assumptions derived from secondary research
- Gathering qualitative and quantitative data on market trends, drivers, and challenges
- Understanding the demand-side dynamics, encompassing end-users, component manufacturers, facility providers, and service providers
- Assessing the supply-side landscape, including technological advancements and recent developments
Market Size Assessment
A combination of top-down and bottom-up approaches was utilized to analyze the overall size of the Pharmacogenomics Market. These methods were also employed to assess the size of various subsegments within the market. The market size assessment methodology encompassed the following steps:
- Identification of key industry players and relevant revenues through extensive secondary research
- Determination of the industry's supply chain and market size, in terms of value, through primary and secondary research processes
- Calculation of percentage shares, splits, and breakdowns using secondary sources and verification through primary sources
.jpg)
Data Triangulation
To ensure the accuracy and reliability of the market size, data triangulation was implemented. This involved cross-referencing data from various sources, including demand and supply side factors, market trends, and expert opinions. Additionally, top-down and bottom-up approaches were employed to validate the market size assessment.
NA